On September 6, 2022 MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA," "the Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, reported that it will present the design of its ongoing THIO-101 trial at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, being held from September 9th to 13th in Paris, France (Press release, MAIA Biotechnology, SEP 6, 2022, View Source [SID1234619094]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
THIO is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). The first patient was enrolled in the THIO-101 study in July 2022 in Australia.
Details of the presentation are as follows:
Abstract title: A Phase 2, Multicenter, Open-Label, Dose-Finding Study Evaluating THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC – A Trial in Progress
Abstract number: 1193
Session title: Trial in Progress (TiP)
Presentation date: Monday, September 12
The full abstract is available on the ESMO (Free ESMO Whitepaper) Congress 2022 website.
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with cemiplimab (Libtayo), a PD-1 inhibitor developed by Regeneron. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second or higher line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.